Colorectal Cancer Therapeutics strategies and Product Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Colorectal Cancer Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope
- Which companies are the most active within the pipeline for colorectal cancer therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Colorectal Cancer Report Coverage 11
2.2 Anal Cancer - Overview 11
2.3 Rectal Cancer - Overview 11
2.4 Colorectal Cancer - Overview 11
3 Therapeutics Development 12
3.1 Anal Cancer 12
3.2 Rectal Cancer 16
3.3 Colorectal Cancer 18
4 Therapeutics Assessment 56
4.1 Anal Cancer 56
4.2 Rectal Cancer 63
4.3 Colorectal Cancer 71
5 Companies Involved in Therapeutics Development 100
5.1 Anal Cancer 100
5.2 Rectal Cancer 108
5.3 Colorectal Cancer 114
6 Dormant Projects 241
6.1 Anal Cancer 241
6.2 Rectal Cancer 241
6.3 Colorectal Cancer 242
7 Discontinued Products 261
7.1 Anal Cancer 261
7.2 Colorectal Cancer 261
8 Product Development Milestones 265
8.1 Anal Cancer 265
8.2 Rectal Cancer 278
8.3 Colorectal Cancer 280
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/colorectal-cancer-therapeutics-strategies-and-product-pipeline-review-2017/250073

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250073

More News From dailytransparent.com

AP Interview: Trump's ex-staffer Scaramucci visits Israel

Nov 20, 2017

JERUSALEM — Washington may not have seen the last of "The Mooch." Anthony Scaramucci, the short-lived White House communications chief who was forced out after just 11 days on the job, said in an interview on Monday that he remains in close touch with the White House. He told The Associated Press that although he has not spoken to Donald Trump in over a month, he talks to members of the president's inner circle "regularly" and sees himself working with Trump again in the future. "I have very good relationships there still, and you have to remember we were a...

Zimbabwe's Mugabe passes deadline to resign; now impeachment

Nov 20, 2017

HARARE, Zimbabwe — Longtime President Robert Mugabe ignored a midday deadline set by the ruling party to step down or face impeachment proceedings, while Zimbabweans stunned by his lack of resignation during a national address vowed more protests to make him leave. "Arrogant Mugabe disregards Zanu PF," one newspaper headline said. Opposition activists and the influential liberation war veterans association announced more demonstrations to pressure the 93-year-old Mugabe, the world's oldest head of state, to step down after 37 year in power. "Your time is up," veterans association leader Chris Mutsvangwa said at a press conference. "You should have the...

The Latest: Dutch minister worried about German uncertainty

Nov 20, 2017

BERLIN — The Latest on Germany's political uncertainty (all times local): 10:50 a.m. The Netherlands' foreign minister says new elections in Germany, the European Union's most populous member, would be "the worst scenario." Dutch Foreign Minister Halbe Zijlstra said in Brussels Monday that "Germany is a very important country in Europe and thus it will become difficult to take important decisions in Brussels." Zijlstra noted that it took the Netherlands seven months to form a new government after an election earlier this year. Coalition talks in Germany collapsed on Sunday night, nearly two months after elections. Zijlstra said: "So I'd...

AP FACT CHECK: Trump oversells results of 'tremendous' trip

Nov 20, 2017

WASHINGTON — Over the past week, President Donald Trump told a made-up story about his predecessor and revived a distorted claim about NATO that's been gathering dust for some months. On those occasions and more, his purpose was to illustrate "tremendous success" on his Asia trip, an extended journey that actually produced little visible or immediate change. He also reached back to earlier travels to make his case. A sampling of his statements toward that goal: TRUMP, summing up a trip he took in May: "In Brussels, I urged our NATO allies to do more to strengthen our crucial alliance...

Philippines' Duterte offers China 3rd telecom carrier slot

Nov 20, 2017

MANILA, Philippines — Philippine President Rodrigo Duterte has offered to China an opportunity to operate a new, third telecommunications carrier in the country, his spokesman said Monday. The move is aimed at breaking a telecoms duopoly in a country that is said to have the slowest internet speed in the Asia Pacific. It is unclear if China or any Chinese companies would be keen to take Duterte up on his offer. Presidential spokesman Harry Roque said Duterte made the offer to Chinese Premier Li Keqiang during their bilateral meeting in Manila last week. The market now is dominated by domestic...